The Obesity-Drug Battle Is Heating Up After Novo's CEO Ouster

The Obesity-Drug Battle Is Heating Up After Novo's CEO Ouster

The Wegovy maker’s executive shift is a sign of just how much it has fallen behind rival Lilly and its Zepbound shot.

Novo's Norwegian chairman in cross-pressureIf the current drama at the top of Novo Nordisk were fiction, there was no doubt that the decisive driving force in the story would be the showdown “Lars vs. Lars” – that is, Lars

Although they are not involved and represent a high cost (can reach EUR 245 per month), the search for these medicines has not stopped growing: sales have almost doubled in the last five years, ranging from 45.790 packages in 2019 to 119.588 in 2024, according to data from the National Pharmacies Association (ANF), based on information from the Health Market Research (HMR).